182 related articles for article (PubMed ID: 34687411)
21. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Chainitikun S; Long JP; Rodriguez-Bautista R; Iwase T; Tripathy D; Fujii T; Ueno NT
Breast Cancer Res Treat; 2020 Oct; 183(3):729-739. PubMed ID: 32720114
[TBL] [Abstract][Full Text] [Related]
23. Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
Paplomata E; Zelnak A; Santa-Maria CA; Liu Y; Gogineni K; Li X; Moreno CS; Chen Z; Kaklamani V; O'Regan RM
Clin Breast Cancer; 2019 Jun; 19(3):188-196. PubMed ID: 30745109
[TBL] [Abstract][Full Text] [Related]
24. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
25. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
Chen Z; Ouyang Q; Wang Y; Wang J; Wang H; Wu X; Zhang P; Huang J; Zheng Y; Cao W; Shao X; Xie N; Tian C; Liang H; Wang C; Zhang Y; Ren D; Wang X
Front Oncol; 2022; 12():829693. PubMed ID: 35311126
[TBL] [Abstract][Full Text] [Related]
26. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
[TBL] [Abstract][Full Text] [Related]
28. Relationship between endocrine resistance and the periods of adjuvant endocrine treatment for hormone receptor-positive, HER2-negative breast cancer.
Yamamura J; Miyamura Y; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hahimot Y; Ito T; Komoike Y
Breast Dis; 2022; 41(1):109-114. PubMed ID: 34420939
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
Iwamoto T; Fujisawa T; Shien T; Araki K; Sakamaki K; Sangai T; Kikawa Y; Takao S; Nishimura R; Takahashi M; Aihara T; Mukai H; Taira N
Breast Cancer; 2020 Sep; 27(5):973-981. PubMed ID: 32394413
[TBL] [Abstract][Full Text] [Related]
30. Survival in patients with HR+/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.
Simon J; Chaix M; Billa O; Kamga AM; Roignot P; Ladoire S; Coutant C; Arveux P; Quantin C; Dabakuyo-Yonli TS
Br J Cancer; 2020 Sep; 123(7):1071-1077. PubMed ID: 32678278
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study.
Yuan Y; Zhang S; Yan M; Yin Y; Song Y; Jiang Z
Ann Transl Med; 2021 May; 9(10):831. PubMed ID: 34164465
[TBL] [Abstract][Full Text] [Related]
32. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
33. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
Malorni L; Curigliano G; Minisini AM; Cinieri S; Tondini CA; D'Hollander K; Arpino G; Bernardo A; Martignetti A; Criscitiello C; Puglisi F; Pestrin M; Sanna G; Moretti E; Risi E; Biagioni C; McCartney A; Boni L; Buyse M; Migliaccio I; Biganzoli L; Di Leo A
Ann Oncol; 2018 Aug; 29(8):1748-1754. PubMed ID: 29893790
[TBL] [Abstract][Full Text] [Related]
34. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
35. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
36. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W; Heudel PE; Fraisse J; Gourgou S; Guiu S; Dalenc F; Pistilli B; Campone M; Levy C; Debled M; Leheurteur M; Chaix M; Lefeuvre C; Goncalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Courtinard C; Cottu P; Robain M; Mailliez A
Int J Cancer; 2019 Dec; 145(12):3359-3369. PubMed ID: 31087564
[TBL] [Abstract][Full Text] [Related]
37. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
38. Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China.
Li Y; Mo H; Guan X; Lin S; Wang Z; Chen Y; Chen S; Li Q; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B
Breast; 2022 Feb; 61():129-135. PubMed ID: 34995922
[TBL] [Abstract][Full Text] [Related]
39. Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Xie Y; Zhao Y; Gong C; Chen Z; Zhang Y; Zhao Y; Yuan P; Hu S; Li Y; Hu X; Zhang J; Wang L; Wang B
Sci Rep; 2019 Feb; 9(1):1710. PubMed ID: 30737426
[TBL] [Abstract][Full Text] [Related]
40. Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Loft M; Lok SW; De Boer R; Malik L; Greenberg S; Yeo B; Anton A; Nottage M; Wong V; Nott L; Collins IM; Torres J; Barnett F; Lombard JM; Gibbs P; Gately L
Breast Cancer Res Treat; 2023 Feb; 198(1):67-74. PubMed ID: 36624321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
